Track AbCellera Biologics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AbCellera Biologics Inc. ABCL Open AbCellera Biologics Inc. in new tab

3.52 USD
EPS
-0.49
P/B
1.02
ROE
-14.48
Beta
0.87
Target Price
9.17 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
EPS-0.49
Book Value3.22
Price to Book1.02
Debt/Equity14.81
% Insiders22.752%
Growth
Revenue Growth7.88%
Estimates
Forward P/E-4.26
Forward EPS-0.77
Target Mean Price9.17

DCF Valuation

Tweak assumptions to recompute fair value for AbCellera Biologics Inc. (ABCL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

AbCellera Biologics Inc. Logo AbCellera Biologics Inc. Analysis (ABCL)

Canada Health Care Official Website Stock

Is AbCellera Biologics Inc. a good investment? AbCellera Biologics Inc. (ABCL) is currently trading at 3.52 USD. Market analysts have a consensus price target of 9.17 USD. This suggests a potential upside from current levels.

Earnings Schedule: AbCellera Biologics Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is -0.77.

Investor FAQ

Does AbCellera Biologics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AbCellera Biologics Inc.?

AbCellera Biologics Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -0.49.

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Exchange Ticker
NMS (United States) ABCL
FRA (Germany) 8QQ.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion